Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief scientific officer, and Tran will lead HR efforts as chief people officer.
Part A of the Phase 2 study ANAVEX ® 3-71-SZ-001 ( NCT06245213 ), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX ® 3-71 90 mg daily, or oral ...